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Abstract We show here that insulin and insulin antagonists
differentially modify phosphorylation of three phospho-isoforms
of P20 (termed S1, S2 and S3) in rat skeletal muscle. Precise
phosphorylation sites of S1 and S2 were mapped to serine 157
and serine 16 respectively. Insulin evoked phosphorylation of P20
at serine 157 through the phosphatidylinositol (PI) 3-kinase
pathway. Epinephrine and calcitonin gene-related peptide
decreased phosphorylation at serine 157 and increased phospho-
rylation at serine 16 and other unidentified sites. These results
demonstrate that the PI-3-kinase pathway of anabolic insulin and
the cAMP pathway of catabolic hormones converge on P20 and
suggest a potential role of this protein in regulating energy
metabolism of skeletal muscle.
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1. Introduction
In animals, hormones play a central role in controlling in-
tracellular metabolism. Catabolic hormones such as epineph-
rine, glucagon, calcitonin gene-related peptide (CGRP) and
amylin, can evoke the cAMP-mediated signalling cascade in
their respective target tissues, thus inhibiting glycogen synthe-
sis and promoting glycogenolysis and lipolysis [1^3]. On the
other hand, insulin increases the synthesis and storage of car-
bohydrate, lipid and protein and also inhibits their degrada-
tion. Insulin initiates its biological functions on target tissues
by binding with the K-subunits of its receptor on the plasma
membrane and activating the intrinsic tyrosine kinase activity
of the L-subunit [4]. This is followed by the autophosphory-
lation of the receptor and the tyrosine phosphorylation of its
substrates, IRSs (insulin receptor substrates), which in turn
creates binding sites for several signalling molecules/adapters
including the phosphatidylinositol 3-kinase (PI-3-kinase) reg-
ulatory subunit, Shc-1 and Grb2. Subsequently a variety of
serine/threonine protein kinases, such as MAPK (mitogen-ac-
tivated protein kinase), PI-3-kinase, protein kinase B (PKB)
and p70 S6 kinase (p70s6k), are activated to transmit and
amplify the signals of insulin. These multiple protein kinase
cascades exist in parallel but functionally interlink to co-ordi-
nately regulate insulin’s ¢nal metabolic functions.
Anabolic insulin and the catabolic hormones can antago-
nise each other’s metabolic functions by cross-regulating their
respective signal transduction cascades [5^7]. For example, the
cAMP-mediated pathway inactivates glycogen synthase and
activates glycogen phosphorylase by evoking their phosphor-
ylation. On the other hand, insulin acts conversely by pro-
moting dephosphorylation or inhibiting phosphorylation of
these two enzymes [8,9]. Although the actions of insulin and
its physiological antagonists are believed to be mediated by
phosphorylation/dephosphorylation of key intracellular pro-
teins and a great number of protein kinases/phosphatases
have been identi¢ed, relatively few downstream phosphopro-
teins have been isolated.
Recently, we have demonstrated that phosphorylation of
P20 is responsive to amylin in rat skeletal muscle [10]. P20
is a small heat shock-related protein which is mainly expressed
in skeletal muscle [11]. Here, we provide evidence that signal-
ling pathways of insulin and the counter-regulatory hormones
epinephrine and CGRP also converge on P20, and that these
hormones di¡erentially modify the phosphorylation of the
three isoforms of this protein. The phosphorylation sites for
each isoform have been characterised and the upstream events
responsible for these phosphorylations have been analysed
and discussed.
2. Materials and methods
2.1. Preparation of 32P-labelled muscle strips and two-dimensional gel
electrophoresis (2-DE)
Rat extensor digitorum longus (EDL) muscle strips were prepared
and radiolabelled with [32P]orthophosphate (ICN) as previously de-
scribed [10]. The labelled muscle strips were stimulated with human
insulin (Actrapid, Novo Nordisk), epinephrine (David Bull laborato-
ries), rat CGRP-1 (CGRP; Bachem, Torrance, CA) for 1 h at stated
¢nal concentrations. The muscle samples were then solubilised and
aliquots of lysates with equivalent amounts of radioactivity were sep-
arated by 2-DE as before [10]. After electrophoresis the proteins were
visualised using autoradiography, phosphorimaging or staining with
Coomassie brilliant blue (CBB). In all ¢gures, the gels are displayed
with the acid end of the isoelectric focusing dimension to the right and
the direction of SDS-PAGE from top to bottom. All the results pre-
sented are based on at least three independent experiments.
2.2. Isolation of the tryptic phosphopeptides by reversed-phase high
performance liquid chromatography (RP-HPLC)
32P-labelled proteins separated by CBB-stained preparative 2-DE
were excised and gel pieces were subjected to in-gel trypsin digestion
as described by Rosenfeld et al. [12]. The digested peptides were frac-
tionated by RP-HPLC on a Jupiter 5W C18 column (25U0.2 cm,
Phenomenex). The pre-heated column (37‡C) was washed for 10 min
with 0.1% tri£uoroacetic acid (v/v) followed by elution using a 30-min
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linear gradient from 4% acetonitrile to 56% acetonitrile at a £ow rate
of 300 Wl/min. Fractions were collected manually and 32P-labelled
phosphopeptides were detected by liquid scintillation counting.
2.3. Matrix-assisted laser desorption ionisation time of £ight mass
spectrometry (MALDI-TOF/MS)
Aliquots of phosphopeptide separated by RP-HPLC were mixed
with an equal amount of K-cyano-4-hydroxycinnamic acid. The mix-
ture was loaded on the probe tip and vacuum-crystallised by using the
sample preparation accessory (Hewlett-Packard). The MALDI mass
spectrum of the peptide was then obtained on a G2025A MALDI-
TOF mass spectrometer (Hewlett-Packard). Mass analysis of Glu-C-
digested peptide mixtures was performed using a PerSeptive Biosys-
tems Voyager DE mass spectrometer; this instrument was operated in
the delayed extraction mode with external calibration against a series
of synthetic peptides.
2.4. Two-dimensional phosphopeptide mapping
Trypsin-digested 32P-radiolabelled peptide mixtures from three
phosphoforms of P20 were lyophilised and solubilised in 10 Wl of
electrophoresis bu¡er (1% pyridine/10% acetic acid, pH 3.5). The dis-
solved sample solution was spotted in the middle of a thin layer
chromatography plate (20 cmU20 cm; Sigma) 4 cm from the bottom
with a trace of basic Fuchsin dye. Electrophoresis was carried out at
350 V, until the basic Fuchsin dye had migrated 2.5 cm towards the
cathode. The plates were air-dried and subjected to the perpendicular
dimensional chromatography in pyridine/butanol/acetic acid/water
(10:15:3:12, v/v) until the solvent front reached the top of the plate.
Plates were air-dried and phosphopeptides detected by autoradiogra-
phy.
2.5. Phosphate release analysis
Peptides were sequenced with a Hewlett-Packard G1000A protein
sequencer utilising Routine 3.1 Edman degradation chemistry as rec-
ommended by the manufacturer. Phosphopeptides were covalently
linked to Sequelon AA ¢lters using the Sequelon AA Reagent Kit
(Millipore), and phosphate was extracted at each cycle with three
0.5-ml volumes of 90% methanol, 0.015% phosphoric acid as the
solvent in the Routine 3.1 PVDF method. Extracted cycles were di-
verted via valve number RV6 (line 61), collected directly into fraction
collector tubes, and counted on a liquid scintillation counter.
3. Results
3.1. P20 is a common target of insulin and several antagonistic
hormones
We have recently found that phosphorylation of three iso-
forms of P20 is modi¢ed by amylin [10]. To further investigate
the e¡ects of insulin and the antagonistic hormones, epineph-
rine and CGRP, on phosphorylation of P20, proteins ex-
tracted from 32P-labelled rat EDL muscle strips stimulated
by these hormones were separated by analytical 2-DE. Quan-
titative analysis using phosphorimaging revealed that these
metabolic hormones reproducibly alter phosphorylation of
the three isoforms of P20 (termed S1 with pI 6.0, S2 with
pI 5.9 and S3 with pI 5.6). Insulin increased phosphorylation
of S1 by 2.3-fold compared with that of control muscles (Fig.
1A,B). In contrast, epinephrine decreased phosphorylation of
S1 by 1.9-fold but increased phosphorylation of S2 and S3 by
8.2-fold and 3.7-fold respectively (Fig. 1C). The e¡ects of
CGRP on phosphorylation of S1, S2 and S3 were similar to
that of epinephrine (Fig. 1D). Thus we concluded that the
signalling cascades of insulin and several of its physiological
antagonists converge on P20 and di¡erentially in£uence the
phosphorylation of this protein.
3.2. Two-dimensional phosphopeptide mapping of in vivo
phosphorylated isoforms of P20
To directly analyse the patterns of radioactive peptides gen-
erated from the three phosphorylated isoforms of P20, 32P-
radiolabelled S1, S2 and S3 were individually excised from the
preparative 2-DE gels and trypsin-digested as above. The
tryptic peptide mixtures were separated by two-dimensional
phosphopeptide mapping and detected by autoradiography.
The results showed that both S1 and S2 contained only a
Fig. 1. Phosphorylation of P20 is associated with actions of insulin
and two antagonistic hormones. 32P-radiolabelled EDL muscle strips
were incubated for 1 h (A) without or (B) with 100 nM insulin, (C)
100 nM epinephrine, or (D) 100 nM CGRP. Muscle lysates with
equivalent amounts of radioactivity were separated by 2-DE and the
phosphorylation of the three isoforms of P20 was quantitated by
phosphorimaging.
Fig. 2. Comparison of two-dimensional tryptic phosphopeptide
maps obtained from the three major phosphorylated species of P20.
32P-radiolabelled muscle lysates were resolved by 2-DE and the
spots corresponding to the three phosphorylated isoforms of P20
(S1, S2 and S3) were excised from the gels and digested by trypsin.
The tryptic products from S1, S2 and S3, or their respective mix-
tures (S1+S2, S1+S3, S2+S3), were then separated by two-dimen-
sional phosphopeptide mapping and analysed by autoradiography
as described in Section 2.
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single prominent 32P-labelled phosphopeptide (Fig. 2). When
the tryptic digests from S1 and S2 were mixed and run togeth-
er, the resulting phosphopeptides migrated as di¡erent spots
on the plate, suggesting that phosphorylation sites of S1 and
S2 are di¡erent. In contrast, three 32P-labelled phosphopepti-
des were detected from the tryptic peptide mixture of S3. One
of these phosphopeptides co-migrated with that of S2. The
positions of the other two peptides were distinct from those
of S1 and S2. These data indicate that the phosphorylation
sites of these three isoforms of P20 are di¡erent from each
other.
3.3. Isolation and identi¢cation of the phosphopeptides from S1
and S2
To precisely determine which tryptic peptides were phos-
phorylated, the tryptic digests of 32P-labelled S1 or S2 derived
from 18 pieces of 2-DE gels were separated by RP-HPLC and
aliquots from each fraction were counted for 32P-radioactiv-
ity. The result showed that fraction a, from S1 (termed S1-a)
and fraction b, from S2 (termed S2-b) contained 32P-radio-
labelled phosphopeptides (Fig. 3). Fraction S1-a was eluted at
17.5 min and 35% acetonitrile while fraction S2-b was eluted
at 12 min and 24% acetonitrile. Analysis using two-dimen-
sional phosphopeptide mapping revealed that the distribution
patterns of S1-a and S2-b on TLC plates were exactly the
same with their corresponding tryptic peptide mixtures (data
not shown), further con¢rming that only a single tryptic pep-
tide was phosphorylated in S1 and S2. Subsequent phospho-
amino acid analysis showed that both the isolated phospho-
peptides are phosphorylated on serine residues (data not
shown).
MALDI-TOF/MS analysis was carried out to determine the
identity of the two puri¢ed phosphopeptides from S1 and S2.
This result revealed that fraction S2-b contained a single tryp-
tic peptide with molecular mass of 1494.1 Da (Fig. 4A), which
is 81 Da larger than the theoretical mass of the tryptic peptide
between residues 14 and 27 of P20, suggesting that this pep-
tide is mono-phosphorylated (Table 1). In fraction S1-a, two
peptides with molecular masses of 3846.9 Da and 4166.5 Da
respectively were detected by MALDI-TOF/MS analysis (Fig.
4B). The masses of these two peptides are 81 Da larger than
the predicted masses of the incomplete trypsin cleavage prod-
Fig. 3. Puri¢cation and identi¢cation of 32P-labelled tryptic phos-
phopeptides of P20. Two 32P-radiolabelled isoforms of P20 (S1, S2)
were excised from 2-DE gels, digested by trypsin and separated by
RP-HPLC as described in Section 2. The radioactivity of each frac-
tion was determined by liquid scintillation counting and the frac-
tions containing 32P are indicated by a and b.
Fig. 4. Mass spectra of the 32P-labelled phosphopeptides puri¢ed in Fig. 3. Fraction S2-b (A) and fraction S1-b (B) were analysed by MALDI-
TOF/MS as described in the text. The phosphopeptide S1-a was further digested with Glu-C proteinase (0.5 Wg in 50 Wl) for 16 h at 37‡C in
20 mM NH4HCO3, pH 8.0 and analysed by mass spectrometry 4(C).
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uct corresponding to residues 121^162 and complete tryptic
product from residues 123^162 respectively (Table 1). This
result indicated that a single residue between 123 and 162 is
phosphorylated. There are six serine residues within this re-
gion. To generate shorter 32P-labelled peptides, the original
tryptic peptide in fraction S1-a was further digested with en-
dopeptidase Glu-C. MS analysis indicated that the Glu-C
protease-digested mixture contained three major peptides
(Fig. 4C). Peptides with masses of 1619.49 Da and 1939.54
Da can be assigned to fragments corresponding to residues
123^139 and residues 121^139 respectively (Table 1). The
mass of 2240.44 Da matched the mass of the mono-
phosphorylated peptide containing residues 140^162, suggest-
ing that the phosphorylated residue is located within this re-
gion.
3.4. The precise phosphorylation sites of S1 and S2 are located
at serine 157 and serine 16 respectively
The above results revealed that the phosphorylation of
S1 and S2 occurred within residues (GVLSIQATPASA-
QASLPSPP) from 140 to 162 and residues (RASAPLPGFST)
from 14 to 27 individually. To determine the precise phos-
phorylation sites for the two isoforms, the phosphopeptides
in S2-b and Glu-C digested S1-a were subjected to automated
solid-phase N-terminal sequence analysis and 32P released
from each cycle of Edman degradation was counted for radio-
activity. The results showed that the majority of 32P was re-
leased at cycle 3 for S2-b and cycle 18 for Glu-C digested S1-a
(Fig. 5). Thus, we conclude that the phosphorylated residues
of S1 and S2 are located at serine 157 (LPSPP) and serine 16
(RRAS) respectively. Interestingly, serine 157 is located near
the COOH-terminus of P20 while serine-16 is adjacent to the
NH2-terminus.
3.5. Insulin-evoked phosphorylation of S1 is a downstream
event of PI-3-kinase activation
The downstream events of the insulin-evoked PI-3-kinase
signalling cascade play a central role in controlling fuel me-
Fig. 5. Phosphate release analysis of the 32P-labelled peptides puri-
¢ed from S1 and S2. Fraction S2-b (A) or Glu-C-digested fraction
S1-a (B) were subjected to N-terminal sequencing and 32P released
from each cycle was quantitated. The corresponding amino acid res-
idues released from each cycle are shown at the top of each chart.
Fig. 6. E¡ects of wortmannin and rapamycin on insulin-evoked
phosphorylation at serine 157. 32P-prelabelled muscle strips were (A)
untreated, treated with (B) 100 nM insulin, (C) 100 nM insulin plus
1 WM wortmannin, or (D) 100 nM insulin plus 200 nM rapamycin
for 1 h. Wortmannin and rapamycin were added 30 min before the
addition of insulin. Muscle lysates were separated by 2-DE and ana-
lysed by phosphorimaging. The bar chart represents the increased
percentage of radioactivity in P20 isoform S1 relative to that in the
untreated muscle strips.
Table 1
Mass determinations of 32P-labelled phosphopeptides from S1 and S2
Mass (observed) Mass (theoretical) Mass (theoretical+Pi) Position Peptide sequence
1494.1 Da 1413.6 Da 1493.6 Da 14^27 RASAPLPGFSTPGR
3846.9 Da 3765.2 Da 3845.2 Da 123^162 LPPGVDPAAVTSALSPEGVLSIQATPASAQASLPSPPAAK
4166.5 Da 4084.6 Da 4164.6 Da 121^162 YRLPPGVDPAAVTSALSPEGVLSIQATPASAQASLPSPPAAK
1619.4 Da 1620.8 Da 123^139 LPPGVDPAAVTSALSPE
1939.5 Da 1941.2 Da 121^139 YRLPPGVDPAAVTSALSPE
2240.4 Da 2163.4 Da 2243.4 Da 140^162 GVLSIQATPASAQASLPSPPAAK
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tabolism. To investigate whether the insulin-evoked phosphor-
ylation of P20 at serine 157 is a downstream target of PI-3-
kinase, pre-radiolabelled muscle strips were treated with insu-
lin, or insulin plus the PI-3-kinase selective inhibitor wort-
mannin, or the p70s6k kinase inhibitor rapamycin, individu-
ally. The phosphorylation of P20 was analysed by 2-DE and
phosphorimager as above. The results showed that insulin-
induced increase in phosphorylation of S1 was completely
blocked by wortmannin but not by rapamycin (Fig. 6). This
suggests that insulin phosphorylates P20 at serine 157 via the
PI-3-kinase pathway but p70s6k kinase is not directly respon-
sible for the phosphorylation.
4. Discussion
Regulation of intracellular metabolism by hormones is
often mediated through phosphorylation/dephosphorylation
of key phosphoproteins. The results of the present study pro-
vide evidence to demonstrate that multiple phosphorylation of
P20 is associated with actions of insulin and several of insulin
antagonists, in rat hind limb skeletal muscle. Rat P20 is com-
posed of 162 amino acid, including 14 serine, 5 threonine and
4 tyrosine residues [11,13]. 2-DE analysis of 32P-labelled
muscle lysates displayed three phosphorylated isoforms of
P20 (S1, S2, S3) with di¡erent pI values. Two-dimensional
phosphopeptide mapping revealed that phosphorylation of
P20 at di¡erent sites accounted for the production of these
three phosphorylated isoforms. The tryptic phosphopeptides
from S1 and S2 were isolated by RP-HPLC and were further
shown to be the mono-phosphorylated fragments correspond-
ing to residues 14^27 and 121^162 respectively. The precise
phosphorylation sites of S1 and S2 were unequivocally
mapped to serine 157 (L-P-S-P-P) and serine 16 (R-R-A-S)
by N-terminal sequencing of the puri¢ed 32P-labelled phos-
phopeptides. We were unable to directly identify the phos-
phorylation sites of S3 due to its low abundance in CBB-
stained gels. However, two pieces of evidence suggested that
serine 16 of S3 was also phosphorylated. (I) Two-dimensional
phosphopeptide mapping demonstrated that one of the tryptic
phosphopeptides of S3 co-migrated with that of S2. (II) Phos-
phorylation of S2 and S3 simultaneously responded to stim-
ulation by the same hormone.
The sequence surrounding serine 16 (R-R-A-S) exactly
matches the recognition motif of protein kinase A [14]. More-
over we found that forskolin also triggers the phosphorylation
of P20 at this site in skeletal muscle (data not shown). We
therefore conclude that epinephrine, CGRP and amylin evoke
phosphorylation of P20 at serine 16 via increasing cAMP-
mediated protein kinase A activity. Insulin-evoked phosphor-
ylation of P20 at serine 157 (L-P-P-S-P) is an event down
stream of PI-3-kinase, since this action was completely
blocked by wortmannin, a selective and irreversible inhibitor
of PI-3-kinase [15] (Fig. 6). It is now apparent that activation
of PI-3-kinase is indispensable and in some cases su⁄cient to
elicit insulin’s actions in controlling fuel metabolism [16]. Sev-
eral kinases involved in insulin’s metabolic functions, such as
PDK, PKB/cAkt and p70s6k, act as the downstream e¡ectors
of PI-3-kinase [4]. However, LPPSP does not explicitly con-
form to the substrate recognition motif of these kinases. Fur-
ther study is required to identify the kinase that directly re-
sponsible for insulin-induced phosphorylation of P20 at serine
157.
Several recent studies have suggested that function of P20
might be linked to muscle contractile activity [17^19]. Phos-
phorylation of P20 was responsive to stimulation by agents
that induce either contraction or relaxation of muscle. Inter-
estingly, histamine- and phorbol ester-induced contractions of
bovine carotid artery smooth muscle are associated with an
increase in phosphorylation of a P20 isoform which is equiv-
alent to insulin-induced S1 in rat skeletal muscle [20]. Both
CGRP and amylin have the ability to regulate muscle con-
tractile activity, such as stimulation of vasorelaxation [21] and
inhibition of electrically stimulated muscle contraction [22,23].
Notably, the contractile status of muscle is also an important
factor in regulating glucose metabolism [24]. Insulin and
muscle contraction can enhance each other’s sensitivity and
synergistically stimulate glucose transport [25,26]. Moreover,
both insulin- and contraction-stimulated glucose transport can
be blocked by wortmannin [27] and calcium channel blocker
[28]. Based on these observations, we suggest that the signal-
ling cascades evoked by stimuli leading to muscle contraction/
relaxation stimuli, as well as insulin and catabolic hormones
such as epinephrine, CGRP and amylin, might converge on
P20, and, by regulating the phosphorylation of this protein,
contribute to the co-ordinate regulation of muscle functions
such as contractile activity and energy metabolism. Further
study is required to test this hypothesis.
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